These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Review article: Probiotics in gastrointestinal and liver diseases. Jonkers D; Stockbrügger R Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():133-48. PubMed ID: 18081657 [TBL] [Abstract][Full Text] [Related]
23. Probiotics in hepatology. Lata J; Jurankova J; Kopacova M; Vitek P World J Gastroenterol; 2011 Jun; 17(24):2890-6. PubMed ID: 21734800 [TBL] [Abstract][Full Text] [Related]
24. Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy. Rivera-Flores R; Morán-Villota S; Cervantes-Barragán L; López-Macias C; Uribe M Nutrition; 2020 May; 73():110693. PubMed ID: 32065881 [TBL] [Abstract][Full Text] [Related]
25. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Patel R; DuPont HL Clin Infect Dis; 2015 May; 60 Suppl 2(Suppl 2):S108-21. PubMed ID: 25922396 [TBL] [Abstract][Full Text] [Related]
26. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Degirolamo C; Rainaldi S; Bovenga F; Murzilli S; Moschetta A Cell Rep; 2014 Apr; 7(1):12-8. PubMed ID: 24656817 [TBL] [Abstract][Full Text] [Related]
27. Liver-Microbiome Axis in Health and Disease. Adolph TE; Grander C; Moschen AR; Tilg H Trends Immunol; 2018 Sep; 39(9):712-723. PubMed ID: 29843959 [TBL] [Abstract][Full Text] [Related]
28. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Dhiman RK; Rana B; Agrawal S; Garg A; Chopra M; Thumburu KK; Khattri A; Malhotra S; Duseja A; Chawla YK Gastroenterology; 2014 Dec; 147(6):1327-37.e3. PubMed ID: 25450083 [TBL] [Abstract][Full Text] [Related]
29. [Probiotics in chronic liver diseases]. Wunsch E; Marlicz W; Milkiewicz P Pol Merkur Lekarski; 2010 Dec; 29(174):390-4. PubMed ID: 21298992 [TBL] [Abstract][Full Text] [Related]
30. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. Zhang HL; Yu LX; Yang W; Tang L; Lin Y; Wu H; Zhai B; Tan YX; Shan L; Liu Q; Chen HY; Dai RY; Qiu BJ; He YQ; Wang C; Zheng LY; Li YQ; Wu FQ; Li Z; Yan HX; Wang HY J Hepatol; 2012 Oct; 57(4):803-12. PubMed ID: 22727732 [TBL] [Abstract][Full Text] [Related]
31. The Gut Microbiota and Nonalcoholic Fatty Liver Disease. Quigley EM; Monsour HP Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643 [TBL] [Abstract][Full Text] [Related]
37. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. Al-Muzafar HM; Amin KA BMC Complement Altern Med; 2017 Jan; 17(1):43. PubMed ID: 28086768 [TBL] [Abstract][Full Text] [Related]
38. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Federico A; Dallio M; Godos J; Loguercio C; Salomone F Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867 [TBL] [Abstract][Full Text] [Related]
39. Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis. Dazıroğlu MEÇ; Yıldıran H Ann Gastroenterol; 2023; 36(2):141-148. PubMed ID: 36864944 [TBL] [Abstract][Full Text] [Related]
40. Implication of the intestinal microbiome in complications of cirrhosis. Bhat M; Arendt BM; Bhat V; Renner EL; Humar A; Allard JP World J Hepatol; 2016 Sep; 8(27):1128-1136. PubMed ID: 27721918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]